ECGI Holdings, Inc. (ECGI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ECGI Holdings, Inc. (ECGI) trades at $0.00 with AI Score 50/100 (Grade B). ECGI Holdings, Inc. operates in the cardiac medical device industry, focusing on patient monitoring and cardiac event prediction. Market cap: $6,891, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for ECGI: ECGI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ECGI against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ECGI: the 1 perspectives are evenly split.
How is this calculated? →ECGI Holdings, Inc. (ECGI) Healthcare & Pipeline Overview
ECGI Holdings, Inc. is a cardiac medical device company focused on innovation in patient monitoring and cardiac event prediction. Its leadless cardiac monitor, Now Cardio, aims to provide dual-functionality in holter monitoring and event recording. The company operates in the competitive medical devices sector, targeting improved cardiac care solutions.
What Is the Investment Thesis for ECGI?
ECGI Holdings, Inc. presents a high-risk, high-reward investment profile due to its early-stage development and focus on the competitive cardiac medical device market. The company's success hinges on the successful development, regulatory approval, and commercialization of its Now Cardio device. With a market capitalization of 7K and negative profitability metrics (P/E of -0.16, Profit Margin of -121343.7%, and Gross Margin of -7996.1%), the company's financial viability depends on securing additional funding and achieving significant revenue growth. Key catalysts include successful clinical trials and FDA clearance. The company's beta of 0.17 suggests low volatility relative to the market. Investors should carefully consider the risks associated with investing in an OTC-listed company with limited operating history and negative financial performance.
Based on FMP financials and quantitative analysis
ECGI Key Highlights
- Market Cap of 7K indicates the company's small size and early stage of development.
- P/E Ratio of -0.16 reflects the company's current lack of profitability.
- Profit Margin of -121343.7% highlights significant operational challenges and high expenses.
- Gross Margin of -7996.1% indicates substantial costs associated with the company's product development and operations.
- Beta of 0.17 suggests the stock's price is less volatile than the overall market.
Who Are ECGI's Competitors?
ECGI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
| OWLT Owlet, Inc. | $5.91 | +2.60% | $106.94M | 58 |
| NXL Nexalin Technology, Inc. | $0.35 | -3.07% | $7.20M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ECGI's Key Strengths?
- Innovative wireless and leadless cardiac monitoring technology.
- Dual-functionality of Now Cardio device.
- Potential for AI integration to enhance diagnostics.
- Focus on cardiac event prediction.
What Are ECGI's Weaknesses?
- Limited operating history and small market capitalization.
- Negative profitability and high expenses.
- Dependence on successful development and commercialization of Now Cardio.
- OTC listing indicates higher risk and lower liquidity.
What Could Drive ECGI Stock Higher?
- Successful completion of clinical trials for Now Cardio.
- FDA clearance and regulatory approval for Now Cardio.
- Strategic partnerships with healthcare providers.
- Development of AI-powered analytics for cardiac event prediction.
What Are the Key Risks for ECGI?
- Financial-distress signal — its Altman Z-Score of -7.52 sits in the distress zone (elevated bankruptcy risk).
- Delays or failures in clinical trials.
- Rejection or delays in FDA approval process.
- Intense competition from established medical device companies.
- Challenges in securing funding and achieving profitability.
- Technological obsolescence of cardiac monitoring technology.
What Are the Growth Opportunities for ECGI?
- Expansion into Remote Patient Monitoring: The remote patient monitoring (RPM) market is experiencing rapid growth, driven by the increasing adoption of telehealth and the need for continuous health monitoring. ECGI can capitalize on this trend by integrating its Now Cardio device into RPM platforms, providing real-time cardiac data to healthcare providers. The global RPM market is projected to reach $175.2 billion by 2027, offering a substantial growth opportunity for ECGI.
- Strategic Partnerships with Healthcare Providers: Collaborating with hospitals, clinics, and cardiac rehabilitation centers can provide ECGI with access to a broader patient base and accelerate the adoption of its Now Cardio device. These partnerships can facilitate clinical trials, generate real-world evidence, and establish credibility within the medical community. Securing key partnerships will be crucial for ECGI's market penetration and revenue growth.
- Geographic Expansion: Initially focusing on the US market, ECGI can expand its reach into international markets, particularly in Europe and Asia, where the prevalence of cardiovascular diseases is high and the demand for advanced cardiac monitoring solutions is growing. International expansion requires navigating different regulatory landscapes and adapting the product to local market needs, but it offers significant long-term growth potential.
- Development of AI-Powered Analytics: Integrating artificial intelligence (AI) and machine learning (ML) algorithms into the Now Cardio device can enhance its ability to predict cardiac events and provide personalized insights to patients and healthcare providers. AI-powered analytics can improve the accuracy of diagnoses, reduce false alarms, and optimize treatment plans. Investing in AI development can differentiate ECGI from its competitors and create a competitive advantage.
- Focus on Wearable Technology Integration: As the market for wearable health technology expands, ECGI can explore integrating its cardiac monitoring capabilities into wearable devices such as smartwatches and fitness trackers. This integration would allow for continuous, non-invasive monitoring of cardiac activity, providing users with valuable insights into their heart health. Collaborating with wearable technology companies can accelerate this integration and expand ECGI's market reach.
What Opportunities Does ECGI Have?
- Expansion into remote patient monitoring market.
- Strategic partnerships with healthcare providers.
- Geographic expansion into international markets.
- Integration with wearable health technology.
What Threats Does ECGI Face?
- Intense competition from established medical device companies.
- Stringent regulatory requirements and potential delays in FDA approval.
- Risk of technological obsolescence.
- Challenges in securing funding and achieving profitability.
What Are ECGI's Competitive Advantages?
- Proprietary wireless and leadless cardiac monitoring technology.
- Dual-functionality of Now Cardio device (holter and event recording).
- Potential for AI-powered analytics to enhance diagnostic capabilities.
- Focus on innovation in cardiac event prediction.
What Does ECGI Do?
ECGI Holdings, Inc., formerly known as Event Cardio Group Inc., was renamed in August 2019 and is based in Los Angeles, California. The company operates in the cardiac medical device innovation, patient monitoring, and cardiac event prediction industry. Through its subsidiary, ECGI Holdings, Inc. is focused on developing advanced cardiac monitoring solutions. Its primary product is Now Cardio, a cardiac monitor designed with wireless and leadless technology. This device offers dual-functionality, serving as both a holter monitor and an event recorder, aiming to provide comprehensive cardiac data for physicians. The company's focus is on creating innovative solutions for cardiac care, with an emphasis on improving patient monitoring and predicting cardiac events. ECGI's strategy revolves around leveraging technology to enhance the accuracy and efficiency of cardiac diagnostics. The company is positioning itself to address the growing need for advanced cardiac monitoring devices in the healthcare sector.
What Products and Services Does ECGI Offer?
- Develops cardiac monitoring devices.
- Focuses on wireless and leadless technology.
- Offers dual-functionality devices for holter monitoring and event recording.
- Aims to improve patient monitoring in cardiac care.
- Works on predicting cardiac events.
- Innovates in the cardiac medical device industry.
How Does ECGI Make Money?
- Develops and manufactures cardiac monitoring devices.
- Sells devices to hospitals, clinics, and healthcare providers.
- Potentially generates revenue through subscription-based monitoring services.
- May license its technology to other medical device companies.
What Industry Does ECGI Operate In?
ECGI Holdings, Inc. operates within the medical device industry, specifically focusing on cardiac monitoring. This sector is characterized by technological advancements, stringent regulatory requirements, and intense competition. The global cardiac monitoring market is projected to grow, driven by the increasing prevalence of cardiovascular diseases and the demand for remote patient monitoring solutions. ECGI competes with established medical device companies and smaller innovators. The company's success depends on its ability to differentiate its Now Cardio device through superior technology, clinical efficacy, and cost-effectiveness.
Who Are ECGI's Key Customers?
- Hospitals and clinics requiring cardiac monitoring equipment.
- Cardiologists and other healthcare professionals.
- Patients needing cardiac monitoring for diagnosis and treatment.
- Cardiac rehabilitation centers.
Company Profile
ECGI Holdings, Inc. operates in the Financial - Conglomerates industry within the Financial Services sector. It is headquartered in Irvine, US. The company is led by CEO Simon Yu. ECGI has traded publicly since 2007.
ECGI Holdings, Inc. (ECGI) Valuation Context
Valued at 7K, ECGI is classified as a micro-cap stock. Relative to its peer group, ECGI's quantitative score of 50/100 is below the peer average of 69/100.
ROE 44%Key Financial Metrics
Return on equity for ECGI Holdings, Inc. stands at 44.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -46.4%, showing how much profit it generates from its asset base. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 4/9Financial Health
ECGI Holdings, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -7.52 places it in the distress zone, a signal of elevated financial risk.
ECGI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Innovative wireless and leadless cardiac monitoring technology.
- Dual-functionality of Now Cardio device.
- Potential for AI integration to enhance diagnostics.
- Focus on cardiac event prediction.
Bear Case
- Limited operating history and small market capitalization.
- Negative profitability and high expenses.
- Dependence on successful development and commercialization of Now Cardio.
- OTC listing indicates higher risk and lower liquidity.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ECGI Latest News
No recent news available for ECGI.
ECGI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ECGI.
Price Targets
Wall Street price target analysis for ECGI.
ECGI MoonshotScore
What does this score mean?
The MoonshotScore rates ECGI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jamie Steigerwald
CEO
Jamie Steigerwald serves as the CEO of ECGI Holdings, Inc. Information regarding Steigerwald's detailed career history, education, and previous roles is not available in the provided data. As CEO, Steigerwald is responsible for leading the company's strategic direction, overseeing operations, and driving the development and commercialization of its cardiac monitoring technology.
Track Record: Due to limited information, Jamie Steigerwald's specific achievements, strategic decisions, and company milestones under their leadership cannot be detailed. The company's recent name change and focus on cardiac monitoring suggest a strategic shift under Steigerwald's guidance.
ECGI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ECGI Holdings, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosures and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Higher potential for fraud and manipulation.
- Greater price volatility.
- Risk of delisting or suspension of trading.
- Verify the company's registration and regulatory filings.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their experience.
- Understand the risks associated with investing in an OTC-listed company.
- Consult with a financial advisor before making any investment decisions.
- Company's focus on developing cardiac monitoring technology.
- Existence of a product (Now Cardio) in development.
- Company's headquarters in Los Angeles, California.
- CEO leadership.
Common Questions About ECGI (Healthcare)
What does ECGI Holdings, Inc. do?
ECGI Holdings, Inc. operates in the cardiac medical device industry, focusing on the development and commercialization of innovative cardiac monitoring solutions. The company's primary product is Now Cardio, a wireless and leadless cardiac monitor designed to provide dual-functionality as both a holter monitor and an event recorder. ECGI aims to improve patient monitoring and cardiac event prediction through its advanced technology, targeting hospitals, clinics, and healthcare providers as its primary customers. The company's success hinges on the successful development, regulatory approval, and market adoption of Now Cardio.
What do analysts say about ECGI stock?
As of March 18, 2026, there is no available analyst coverage or consensus on ECGI Holdings, Inc. due to its small market capitalization, OTC listing, and limited operating history. Key valuation metrics such as price targets and earnings estimates are not available. Investors should conduct their own independent research and consider the risks associated with investing in an early-stage, OTC-listed company before making any investment decisions. The company's future growth depends on the successful commercialization of its Now Cardio device and its ability to secure funding and achieve profitability.
What are the main risks for ECGI?
ECGI Holdings, Inc. faces several significant risks, including the challenges of developing and commercializing a new medical device in a highly competitive industry. The company's success depends on obtaining regulatory approval from the FDA, which can be a lengthy and uncertain process. ECGI also faces the risk of technological obsolescence, as well as the need to secure additional funding to support its operations and growth. As an OTC-listed company, ECGI is subject to lower levels of regulatory oversight and may experience greater price volatility and liquidity constraints.
What are the key factors to evaluate for ECGI?
ECGI Holdings, Inc. (ECGI) holds an AI score of 50/100 (moderate). Not financial advice.
How frequently does ECGI data refresh on this page?
ECGI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ECGI's recent stock price performance?
ECGI Holdings, Inc. (ECGI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative wireless and leadless cardiac monitoring technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ECGI overvalued or undervalued right now?
Valuing ECGI Holdings, Inc. (ECGI) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ECGI?
Before investing in ECGI Holdings, Inc. (ECGI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on ECGI Holdings, Inc. due to its OTC listing and small market capitalization.
- Financial data is based on available information and may not be comprehensive.